Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

I played these 25 cards the most and built so many decks around them — or at least dreamed how they might function in the ...

Nostalgia has become one of the most powerful currencies in Bollywood’s contemporary marketing apparatus. The recycling of ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of debate need to shift to include the question of method of doing political ...

The Arts Council of Princeton (ACP) has announced a three-person exhibition, “Divergent Forms,” featuring the work of artists ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Former Google CEO Eric Schmidt declared his own programming expertise obsolete after watching an AI system autonomously ...